ESSA Pharma Oppenheimer Healthcare Summit 2021

ESSA Pharma presented at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit in September 2021. The company is developing first-in-class N-terminal domain (NTD) inhibitors of the androgen receptor for treating prostate and hormone-driven cancers, with EPI-7386 in Phase 1 clinical development. With $202M in cash reserves, ESSA is advancing its pipeline across resistant metastatic castration-resistant prostate cancer and other indications.